Skip to content
DataLookout
Menu

NCT07902921

STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma

StatusNot Yet Recruiting
PhasePhase 1/2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 16 versions: 16 with changes below.

  1. Minor Start date: Nov 24, 2026 to Nov 25, 2026
  2. Minor Start date: Nov 23, 2026 to Nov 24, 2026
  3. Minor Start date: Nov 22, 2026 to Nov 23, 2026
  4. Minor Start date: Nov 19, 2026 to Nov 22, 2026
  5. Minor Start date: Nov 18, 2026 to Nov 19, 2026
Show 10 earlier versionsHide 10 earlier versions
  1. Minor Start date: Nov 17, 2026 to Nov 18, 2026
  2. Minor Start date: Nov 15, 2026 to Nov 17, 2026
  3. Minor Start date: Nov 12, 2026 to Nov 15, 2026
  4. Minor Start date: Nov 11, 2026 to Nov 12, 2026
  5. Minor Start date: Nov 10, 2026 to Nov 11, 2026
  6. Minor Start date: Nov 9, 2026 to Nov 10, 2026
  7. Minor Start date: Nov 8, 2026 to Nov 9, 2026
  8. Minor Start date: Nov 5, 2026 to Nov 8, 2026
  9. Minor Start date: Nov 4, 2026 to Nov 5, 2026
  10. Minor Start date: Nov 3, 2026 to Nov 4, 2026
  1. Study First Submitted
  • Minor: routine updates

Endpoints

Primary

Phase Ib: Determine the safety of STAR0602 monotherapy in participants with TC, and safety of STAR0602 in combination with nivolumab in participants with NSCLC with or without targetable genomic alterations or mCRPC
Timeframe: Start of therapy through 90 day post last dose safety visit.
Phase II: Determine the clinical efficacy of STAR0602 alone in participants with TC measured by progression free survival (PFS)
Timeframe: Cycle 3 Day 1, Cycle 4 Day 1, then every 8 weeks for the first year and every 12 weeks thereafter until disease progression, start of another systemic therapy, or 5 years after completion of study treatment.

Secondary (4)

To evaluate safety of STAR0602 alone during Phase II
To evaluate the efficacy of STAR0602 + nivolumab as defined by progression free survival (PFS) in participants with NSCLC or mCRPC
Determine the overall response rate (ORR), disease control rate (DCR), duration of response (DOR), and overall survival (OS) of STAR0602 + nivolumab in participants with NSCLC or mCRPC
Determine the overall response rate (ORR), disease control rate (DCR), duration of response (DOR), and overall survival (OS) of STAR0602 in participants with TC

Arms and interventions

Arm 1Experimental

De-escalation doses of STAR0602 + nivolumab

Arm 2Experimental

Optimal biological dose of STAR0602 + nivolumab

Arm 3Experimental

De-escalation doses of STAR0602 monotherapy

Arm 4Experimental

Optimal biological dose of STAR0602 monotherapy

Drugs: STAR0602, Nivolumab

Sites

1 site in 1 country

  • National Institutes of Health Clinical CenterBethesda, Maryland, United States